Raphael Pharmaceutical Inc

Raphael Pharmaceutical Inc. (OTCQB: RAPH) is an Israeli-based pharmaceutical research and development company headquartered in Tel Aviv-Jaffa, Israel, focused on the discovery and clinical development of drug therapies based on cannabinoids, including cannabidiol (CBD) and other biologically active compounds derived from or inspired by the cannabis plant's diverse pharmacological profile. Cannabinoid-based medicine represents an active area of pharmaceutical research globally, building on the scientific community's growing understanding of the endocannabinoid system — the network of receptors, ligands, and regulatory enzymes present throughout the human body that play important roles in pain signaling, immune function, neurological activity, and inflammatory response. Pharmaceutical companies developing cannabinoid-based drug candidates seek to apply the therapeutic mechanisms of these compounds in rigorous clinical programs that establish safety and efficacy evidence necessary for regulatory approval.<br><br>Raphael Pharmaceutical's pipeline includes a completed study for its lead product candidate targeting the treatment of rheumatoid arthritis (RA) — an autoimmune inflammatory disease affecting millions of patients globally for whom existing treatment options, including biologics and conventional disease-modifying anti-rheumatic drugs, do not always achieve adequate disease control or are associated with significant safety concerns. The company is also developing asthma product candidates currently in the pre-clinical stage, where laboratory and animal model studies are conducted to establish the pharmacological rationale and safety profile necessary before proceeding to human clinical trials. The exploration of cannabinoid-based therapies for respiratory inflammatory conditions like asthma reflects the broader scientific interest in the anti-inflammatory properties of CBD and related compounds.<br><br>Raphael Pharmaceutical Inc. trades on the OTCQB Venture Market under the ticker symbol RAPH and has filed registration statements on Form S-1 with the Securities and Exchange Commission, reflecting its efforts to establish and maintain a transparent public reporting profile. As the global pharmaceutical industry's engagement with cannabinoid-based drug development continues to grow — supported by increasing regulatory pathways for cannabis-derived medicines in multiple countries, growing clinical evidence for specific indications, and substantial investor and patient interest — Raphael Pharmaceutical's cannabinoid drug research program represents participation in an emerging pharmaceutical category with significant potential if clinical and regulatory milestones are achieved.